Leveraging the Multidisciplinary Team to Care for Patients with Inflammatory
Bowel Disease and Obesity
Pre-Test
Questions marked with a
*
are required
100%
Please click here to download program overview
Contact Information
First Name
Last Name
Email Address
Which among the following statements is true with in relation to gut inflammation and
obesity ?
Which among the following statements is true with in relation to gut inflammation and obesity ?
BMI can be used as a sole surrogate to capture obesity’s association with IBD given the established immunological activity of the visceral adipose tissue (VAT)
Creeping fat is a type of locally restrictive VAT considered more immunologically active than other VAT, and whose extent correlates with transmural inflammation, fibrosis, muscle hypertrophy, and stricture formation in Crohn’s disease but not in ulcerative colitis
Adipose tissue serves as an energy store with some endocrine functionality, with no immunological, metabolic, and regulatory functions
Premorbid obesity has been consistently linked with an increased risk of developing Crohn’s disease across all studies to date
Mark is a 36-year-old male with a 2.5-year history of Crohn’s disease and a BMI of 37.5
kg/m². He reports difficulty managing the demands of his current job, which requires
prolonged standing, due to ongoing fatigue, joint pain, and worsening diarrhea. He has been
on mesalamine since the time of his initial Crohn’s disease diagnosis. He has not used any
weight-loss medications but expresses concern about his steadily increasing weight over the
past few years and inquires about pharmacologic treatment options for obesity.
What is the most appropriate course of action for managing both Mark’s obesity and
Crohn’s disease?
Mark is a 36-year-old male with a 2.5-year history of Crohn’s disease and a BMI of 37.5 kg/m². He reports difficulty managing the demands of his current job, which requires prolonged standing, due to ongoing fatigue, joint pain, and worsening diarrhea. He has been on mesalamine since the time of his initial Crohn’s disease diagnosis. He has not used any weight-loss medications but expresses concern about his steadily increasing weight over the past few years and inquires about pharmacologic treatment options for obesity. What is the most appropriate course of action for managing both Mark’s obesity and Crohn’s disease?
Increase the dose of mesalamine
Switch to sulfasalazine
Initiate biological therapy
Prescribe a course of prednisolone
Elena is a 42-year-old woman with ulcerative colitis and a BMI of 36.8 kg/m². Despite
treatment with infliximab, she reports increased fatigue and experiences bloody stools 3–4
times per day. She also expresses emotional distress related to her body image and ongoing
dietary restrictions. Elena is interested in working with a team of specialists to address her
health concerns and receive more comprehensive care, but she is unsure how to proceed.
As her gastroenterologist, which of the following best reflects a multidisciplinary strategy to
address Elena’s complex needs?
Elena is a 42-year-old woman with ulcerative colitis and a BMI of 36.8 kg/m². Despite treatment with infliximab, she reports increased fatigue and experiences bloody stools 3–4 times per day. She also expresses emotional distress related to her body image and ongoing dietary restrictions. Elena is interested in working with a team of specialists to address her health concerns and receive more comprehensive care, but she is unsure how to proceed. As her gastroenterologist, which of the following best reflects a multidisciplinary strategy to address Elena’s complex needs?
Refer her to a bariatric surgeon for immediate surgical weight loss intervention.
Initiate a strict calorie-restricted diet and advise her to discontinue infliximab if GI symptoms worsen.
Suggest over-the-counter weight-loss supplements and emphasize on the importance of regular exercise
Collaborate with a hepatologist, endocrinologist registered dietitian, psychologist/psychiatrist, pharmacist, nurse practitioner, and exercise physiologist to tailor an individualized care plan
Catherine, A 42-year-old woman, has been living with ulcerative colitis for the past five
years and is currently being treated with infliximab. Her BMI is 36.5 kg/m². Over the past
several weeks, she has experienced ongoing symptoms, including 4–5 episodes of bloody
diarrhea daily, along with urgency, tenesmus, fatigue, and intermittent abdominal
discomfort. Laboratory results show mildly elevated liver enzymes and fasting glucose
levels. Despite maintaining a healthier diet and engaging in physical activity three times per
week, she feels discouraged by the lack of improvement in her overall health and seeks
additional guidance. Which of the following would be the most appropriate next step in
managing Catherine’s IBD and obesity?
Catherine, A 42-year-old woman, has been living with ulcerative colitis for the past five years and is currently being treated with infliximab. Her BMI is 36.5 kg/m². Over the past several weeks, she has experienced ongoing symptoms, including 4–5 episodes of bloody diarrhea daily, along with urgency, tenesmus, fatigue, and intermittent abdominal discomfort. Laboratory results show mildly elevated liver enzymes and fasting glucose levels. Despite maintaining a healthier diet and engaging in physical activity three times per week, she feels discouraged by the lack of improvement in her overall health and seeks additional guidance. Which of the following would be the most appropriate next step in managing Catherine’s IBD and obesity?
Continue lifestyle modification and initiate a GLP-1 receptor agonist
Recommend daily exercise, stricter dietary restrictions, and continuation of her current medication
Increase the dose of infliximab and add phentermine/topiramate
Prescribe a corticosteroid and add over-the-counter probiotics
Done
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close
drag_indicator
Custom Title
highlight_off